Clinical Scorecard: Long-Term Outcomes of Ublituximab Treatment in Multiple Sclerosis: Findings from the ULTIMATE I and II Open-Label Extension Trials

At a Glance

Key Highlights

• Ublituximab is a glycoengineered anti-CD20 monoclonal antibody with 25- to 30-fold greater ADCC compared to other anti-CD20 therapies.
• ULTIMATE I and II phase 3 trials demonstrated significantly reduced annualized relapse rates and fewer MRI lesions with ublituximab versus teriflunomide over 2 years.
• The ongoing ULTIMATE open-label extension study shows sustained clinical efficacy and safety of ublituximab treatment over 5 years.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of RMS based on clinical criteria and MRI findings as per standard MS diagnostic protocols.

Management

• Use ublituximab for RMS patients to reduce relapse rates and disease activity.
• Administer initial 150 mg infusion over 4 hours followed by 450 mg infusions over 1 hour every 24 weeks.
• Pre-medicate with antipyretics before each infusion to mitigate infusion-related reactions.

Monitoring & Follow-up

• Monitor annualized relapse rate (ARR) and Expanded Disability Status Scale (EDSS) scores for disability progression or improvement.
• Assess Multiple Sclerosis Functional Composite (MSFC) scores yearly to evaluate neurological function.
• Adverse events should be recorded and graded according to standardized criteria; exclude COVID-19 related events due to pandemic bias.

Risks

• Potential infusion-related reactions; premedication recommended.
• Long-term safety profile consistent with anti-CD20 therapies; monitor for infections and other adverse events.

Patient & Prescribing Data

Adults with relapsing multiple sclerosis who completed initial ULTIMATE I or II trials or switched from teriflunomide.

Ublituximab offers effective disease control with lower doses and shorter infusion times compared to other anti-CD20 therapies, supporting long-term use.

Clinical Best Practices

• Ensure informed consent and adherence to ethical guidelines before initiating treatment.
• Follow infusion protocols strictly, including dosing schedule and premedication.
• Regularly evaluate clinical and functional outcomes to guide ongoing therapy.
• Consider patient race and ethnicity as part of demographic data collection per CONSORT guidelines.
• Adapt monitoring strategies during external factors such as pandemics that may impact imaging availability.

References

• ULTIMATE I and II Trial Results
• Mechanisms of Anti-CD20 Monoclonal Antibodies in MS
• Ublituximab Pharmacology and ADCC Enhancement